Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02673333 · ClinicalTrials.gov registry record · Phase 2

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

A Phase 2 study of Adrenocortical Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
39
Enrollment target
2
Study locations

NCT02673333 is a Phase 2 study of Adrenocortical Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants, below the 359-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02673333, a Phase 2 study of Adrenocortical Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.

Conditions Studied

Adrenocortical Carcinoma

Interventions

  • DRUG Pembrolizumab

Study Locations (2)

Michigan

  • University of Michigan (Data or Specimen Analysis Only) - Ann Arbor

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2016-02
Est. Completion 2026-02
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02673333

The ClinicalTrials.gov registry entry for NCT02673333 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 359-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT02673333 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT02673333 about?

NCT02673333 is a clinical study titled "Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma". Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.

What is the current status of trial NCT02673333?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2016-02. Estimated completion is 2026-02.

What conditions does trial NCT02673333 study?

This clinical trial studies the following conditions: Adrenocortical Carcinoma.

What interventions are being tested in trial NCT02673333?

The interventions under investigation include: Pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT02673333?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02673333 being conducted?

This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adrenocortical Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adrenocortical Carcinoma

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.